See more : TaskUs, Inc. (TASK) Income Statement Analysis – Financial Results
Complete financial analysis of Sam Chun Dang Pharm. Co., Ltd (000250.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sam Chun Dang Pharm. Co., Ltd, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Koninklijke Philips N.V. (PHG) Income Statement Analysis – Financial Results
- Gem Diamonds Limited (GMDMF) Income Statement Analysis – Financial Results
- The Furukawa Battery Co., Ltd. (6937.T) Income Statement Analysis – Financial Results
- Elecom Co., Ltd. (6750.T) Income Statement Analysis – Financial Results
- Niraj Ispat Industries Limited (NIRAJISPAT.NS) Income Statement Analysis – Financial Results
Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
About Sam Chun Dang Pharm. Co., Ltd
SAM CHUN DANG PHARM Co., Ltd. engages in the manufacture of pharmaceuticals. Its products include antibiotics, cures for the circulatory and respiratory system, medicines for the digestive system and ophthalmology, and anti-inflammatory. The company was founded on December 29, 1943 and is headquartered in Hwaseong-si, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 192.67B | 177.34B | 167.27B | 166.86B | 186.60B | 159.96B | 160.59B | 147.37B | 132.06B | 118.92B | 104.54B | 76.65B |
| Cost of Revenue | 95.70B | 89.43B | 86.03B | 74.33B | 77.14B | 77.32B | 76.32B | 68.76B | 60.34B | 53.87B | 48.13B | 38.74B |
| Gross Profit | 96.97B | 87.91B | 81.25B | 92.53B | 109.46B | 82.64B | 84.27B | 78.61B | 71.73B | 65.06B | 56.42B | 37.91B |
| Gross Profit Ratio | 50.33% | 49.57% | 48.57% | 55.45% | 58.66% | 51.66% | 52.47% | 53.34% | 54.31% | 54.70% | 53.97% | 49.46% |
| Research & Development | 5.04B | 5.47B | 32.39B | 21.18B | 17.92B | 8.96B | 4.62B | 2.95B | 4.07B | 2.07B | 1.86B | 1.36B |
| General & Administrative | 11.38B | 9.92B | 9.03B | 9.00B | 1.93B | 1.85B | 1.82B | 1.64B | 1.38B | 1.38B | 1.12B | 990.55M |
| Selling & Marketing | 40.61B | 35.20B | 32.28B | 34.86B | 34.73B | 28.35B | 26.05B | 23.37B | 21.13B | 19.43B | 17.39B | 11.53B |
| SG&A | 51.99B | 68.74B | 63.06B | 66.06B | 65.44B | 57.34B | 54.89B | 50.54B | 46.20B | 43.02B | 37.67B | 30.20B |
| Other Expenses | 30.38B | -1.13B | -1.09B | -1.49B | -2.29B | -2.04B | -1.74B | -766.48M | -678.78M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 87.41B | 75.34B | 96.54B | 88.73B | 85.65B | 68.34B | 61.26B | 54.25B | 50.95B | 46.07B | 46.63B | 32.87B |
| Cost & Expenses | 183.02B | 164.77B | 182.56B | 163.06B | 162.79B | 145.66B | 137.58B | 123.01B | 111.29B | 99.94B | 94.75B | 71.61B |
| Interest Income | 2.79B | 2.12B | 1.44B | 1.63B | 2.03B | 1.42B | 1.22B | 1.03B | 946.13M | 1.02B | 183.64M | 983.47M |
| Interest Expense | 2.58B | 2.79B | 1.90B | 638.41M | 816.83M | 231.94M | 197.64M | 940.00 | 141.01M | 498.89M | 917.13M | 29.24M |
| Depreciation & Amortization | 8.43B | 7.65B | 6.74B | 6.69B | 6.49B | 6.30B | 6.25B | 5.36B | 4.22B | 4.08B | 4.11B | 2.32B |
| EBITDA | 6.55B | 19.36B | -10.91B | 23.90B | 26.63B | 21.00B | 30.53B | 28.14B | 25.20B | 23.02B | 19.97B | 7.78B |
| EBITDA Ratio | 3.40% | 11.40% | -5.11% | 6.29% | 16.24% | 12.88% | 18.22% | 20.16% | 18.93% | 19.36% | 19.10% | 10.15% |
| Operating Income | 9.56B | 12.57B | -15.29B | 3.80B | 23.81B | 14.30B | 23.01B | 24.36B | 20.77B | 18.94B | 15.86B | 5.46B |
| Operating Income Ratio | 4.96% | 7.09% | -9.14% | 2.28% | 12.76% | 8.94% | 14.33% | 16.53% | 15.73% | 15.93% | 15.17% | 7.12% |
| Total Other Income/Expenses | -14.02B | -3.31B | -4.26B | 11.06B | -5.89B | -1.04B | -1.17B | -1.70B | 63.88M | 34.01M | -6.25B | 566.47M |
| Income Before Tax | -4.46B | 8.92B | -19.55B | 16.58B | 19.32B | 14.46B | 24.08B | 22.66B | 20.84B | 20.01B | 9.61B | 6.03B |
| Income Before Tax Ratio | -2.31% | 5.03% | -11.69% | 9.94% | 10.35% | 9.04% | 14.99% | 15.37% | 15.78% | 16.82% | 9.19% | 7.86% |
| Income Tax Expense | -271.04M | 87.70M | -9.19B | 9.09B | -282.44M | -131.53M | 3.59B | 7.04B | 2.96B | 2.74B | 2.02B | 4.69B |
| Net Income | -10.38B | 5.84B | -16.56B | -965.68M | 10.45B | 8.75B | 12.51B | 8.71B | 11.63B | 11.85B | 8.72B | 1.34B |
| Net Income Ratio | -5.39% | 3.29% | -9.90% | -0.58% | 5.60% | 5.47% | 7.79% | 5.91% | 8.81% | 9.96% | 8.34% | 1.75% |
| EPS | -463.03 | 264.52 | -750.19 | -44.57 | 488.26 | 408.98 | 585.10 | 422.40 | 570.03 | 572.00 | 449.00 | 69.00 |
| EPS Diluted | -456.23 | 264.52 | -750.19 | -44.57 | 486.59 | 408.98 | 584.76 | 413.05 | 552.65 | 572.00 | 449.00 | 69.00 |
| Weighted Avg Shares Out | 22.42M | 22.07M | 22.07M | 21.67M | 21.41M | 21.41M | 21.39M | 20.62M | 20.40M | 20.71M | 19.43M | 19.43M |
| Weighted Avg Shares Out (Dil) | 22.76M | 22.07M | 22.07M | 21.67M | 21.48M | 21.41M | 21.40M | 21.09M | 21.04M | 20.71M | 19.43M | 19.43M |
Source: https://incomestatements.info
Category: Stock Reports